Log in to search using one of your social media accounts:

 

Zilretta (Triamcinolone Acetonide Extended-Release Injectable Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 20, 2017 Category: Drugs & Pharmacology Source Type: news

FDA OKs First Extended-Release Corticosteroid Shot for Knee OA FDA OKs First Extended-Release Corticosteroid Shot for Knee OA
Triamcinolone acetonide extended-release injectable suspension (Zilretta) is a nonopioid option that provides knee OA pain relief over 12 weeks.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - October 6, 2017 Category: Universities & Medical Training Tags: Rheumatology News Alert Source Type: news

Flexion Therapeutics Announces FDA Approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis Knee Pain
BURLINGTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 6, 2017 Category: Drugs & Pharmacology Source Type: news

Triamcinolone Acetonide Cream (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 13, 2017 Category: Drugs & Pharmacology Source Type: news

Triesence (Triamcinolone Acetonide Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 17, 2017 Category: Drugs & Pharmacology Source Type: news

Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog(R) II Cream
DUBLIN, Aug. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referenci... Biopharmaceuticals, Generics, FDA Perrigo, Mycolog, nystatin, triamcinolone acetonide, candidiasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 16, 2017 Category: Pharmaceuticals Source Type: news

Triamcinolone'Slurry' Comparable to Other Steroids for DME
(MedPage Today) -- Homemade tx cost $29 for multiple injections over several years (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 14, 2017 Category: Cardiology Source Type: news

FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye
The FDA issued a safety alert after serious adverse events were reported in at least 43 patients who received a compounded triamcinolone and moxifloxacin product by intravitreal injection.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Clearside Biomedical launches Phase II diabetic macular edema trial
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the first patient in a Phase II clinical trial of CLS-TA in patients with diabetic macular edema. The trial plans to evaluate Clearside’s suspension formulation of a corticosteroid, triamcinolone acetonide, as a suprachoroidal injection in combination with an intravitreal injection of Eylea, an anti-VEGF agent. Get the full story at our sister site, Drug Delivery Business News. The post Clearside Biomedical launches Phase II diabetic macular edema trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news

Clearside Biomedical highlights interim data from retreatment trial
Clearside Biomedical (NSDQ:CLSD) touted preliminary data from a non-interventional and retrospective trial of patients who participated in the completed Phase II trial of CLS-TA for suprachoroidal administration. Clearside’s formulation of triamcinolone acetonide, in combination with intravitreally administered Eylea, was evaluated as a treatment for macular edema associated with retinal vein occlusion. Get the full story at our sister site, Drug Delivery Business News. The post Clearside Biomedical highlights interim data from retreatment trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news

Allernaze (Triamcinolone Acetonide Nasal Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 2, 2017 Category: Drugs & Pharmacology Source Type: news

IA triamcinolone for knee OA: better QOL at acceptable cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2017 Category: Drugs & Pharmacology Source Type: news

Intra-articular triamcinolone may be less effective than placebo for certain patients with knee OA
Findings from a study published in the May 16 issue of The Journal of the American Medical Association suggest that triamcinolone injection may be less effective than placebo for treatment of symptomatic knee osteoarthritis (OA).  (Source: Orthogate - Latest News)
Source: Orthogate - Latest News - May 20, 2017 Category: Orthopaedics Tags: Featured Editors Choice News Source Type: news

Intra-Articular Corticosteroids Show No Benefit in Knee Osteoarthritis (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Intra-articular triamcinolone does not help relieve knee pain in adults with osteoarthritis — and might even lead … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 17, 2017 Category: Primary Care Source Type: news

Steroid Injections Increased Cartilage Loss in Knee Arthritis Steroid Injections Increased Cartilage Loss in Knee Arthritis
Patients receiving triamcinolone did not report less pain than those receiving saline injections, but showed greater cartilage loss during the 2-year study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Clearside closes patient enrollment in trial for diabetic macular edema therapy
Clearside Biomedical (NSDQ:CLSD) said today that it finished enrollment for the Phase 1/2 study of CLS-TA in patients with diabetic macular edema. The Hulk trial is designed to evaluate the safety and efficacy of a suprachoroidal injection of its suspension formulation of a corticosteroid, triamcinolone acetonide, with and without an intravitreal injection of Eylea in DME patients. The Alpharetta, Ga.-based company said it expects preliminary results from the study in the 2nd half of this year. Get the full story at our sister site, Drug Delivery Business News. The post Clearside closes patient enrollment in trial for...
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news

Clearside inks clinical development deal with EyeKor
Clearside Biomedical (NSDQ:CLSD) said today that it landed a deal with EyeKor Inc. to support its clinical trials. The companies did not disclose any financial details of the agreement. Clearside is conducting a Phase III trial of suprachoroidally administered CLS-TA, its suspension formulation of triamcinolone acetonide, in patients with macular edema associated with non-infectious uveitis. The company is also evaluating its suprachoroidal CLS-TA, in combination with intravitreally administered Eyelea (aflibercept), in patients with macular edema associated with retinal vein occlusion. Get the full story at our siste...
Source: Mass Device - March 31, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Wall Street Beat Clearside Biomedical EyeKor Source Type: news

The use of topical corticosteroides in the treatment of oral lichen planus in Spain: A national survey.
Conclusions: There is a need for national guidelines in treatment for oral lichen planus (treatment criteria, drug, dose, treatment time and method of application of corticosteroid) that can be applied by all professionals who treat this disease. (Source: Dental Technology Blog)
Source: Dental Technology Blog - March 7, 2017 Category: Dentistry Source Type: news

Clearside enrolls first patient in phase III trial of Zuprata combination therapy
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in a phase III trial evaluating Zuprata, its suspension formulation of triamcinolone acetonide, in combination with Eylea for the treatment of macular edema associated with retinal vein occlusion. The trial is slated to enroll 460 patients with retinal vein occulsion to assess the efficacy and safety of the combination therapy. In 1 arm of the study, patients will receive the combination therapy at the beginning of the trial, intravitreal Eylea at week 4 and the combination therapy again at weeks 12 and 24. Patients in the control arm will receive...
Source: Mass Device - February 16, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news

Lupin gets final USFDA nod for Mylan's skin disease cream
The approval is for multiple strengths of 0.025 per cent, 0.1 per cent and 0.5 per cent triamcinolone acetonide cream, said the company. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2017 Category: Pharmaceuticals Source Type: news

Azmacort (Triamcinolone Acetonide (inhalation aerosol)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 13, 2016 Category: Drugs & Pharmacology Source Type: news

Aristocort Forte Injection (Triamcinolone Diacetate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 7, 2016 Category: Drugs & Pharmacology Source Type: news

Triamcinolone Cream (Triamcinolone Acetonide Cream) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 5, 2016 Category: Drugs & Pharmacology Source Type: news

Triamcinolone Lotion (Triamcinolone Acetonide Lotion) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 5, 2016 Category: Drugs & Pharmacology Source Type: news

Triamcinolone Ointment (Triamcinolone Acetonide Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 5, 2016 Category: Drugs & Pharmacology Source Type: news

Kenalog Spray (Triamcinolone Acetonide Topical Aerosol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 5, 2016 Category: Drugs & Pharmacology Source Type: news

Aristospan 5 mg (Triamcinolone Hexacetonide Injection 5 mg) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 5, 2016 Category: Drugs & Pharmacology Source Type: news

Kenalog 10 Injection (Triamcinolone Acetonide Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 5, 2016 Category: Drugs & Pharmacology Source Type: news

Trivaris (Triamcinolone Acetonide Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 16, 2016 Category: Drugs & Pharmacology Source Type: news

Clearside Biomedical launches trial for Zuprata
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in clinical trial of its suspension formulation of corticosteroid triamcinolone acetonide, Zuprata, for the treatment of diabetic macular edema. The Alpharetta, Ga.-based company’s Hulk Phase I/II trial is an open-label, multi-center study designed to evaluate the safety and efficacy Zuprata administered in the suprachoroidal space along with intravitreal aflibercept and as an independent therapy in patients with diabetic macular edema. The trial is slated to enroll 20 patients with equal participation in both arms. Anatomical and ...
Source: Mass Device - November 15, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Optical/Ophthalmic Clearside Biomedical Source Type: news

Clearside Biomedical names VP business development | Personnel Moves, Nov. 8, 2016
Clearside Biomedical (NSDQ:CLSD) today named Rick McElheny as its VP of business development. The Alpharetta, Ga.-based company is developing a microinjector loaded with CLS-TA (triamcinolone acetonide) to treat macular edema. The device is designed to inject the compound in the a 30-µm gap between the choroid and the sclera, called the suprachoroidal space. A pivotal Phase III trial of the treatment is under way. Get the full story at our sister site, Drug Delivery Business News. The post Clearside Biomedical names VP business development | Personnel Moves, Nov. 8, 2016 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 8, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Clearside Biomedical Johnson & Johnson Personnel Moves Source Type: news

Nystatin and Triamcinolone Acetonide (Nystatin and Triamcinolone Acetonide Cream, Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 6, 2016 Category: Drugs & Pharmacology Source Type: news

Triamcinolone Hexacetonide Injectable Suspension (Aristospan) (Updated - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - August 30, 2016 Category: Drugs & Pharmacology Source Type: news

Glenmark gets FDA nod for skin ointment
Approval has been granted for generic version of triamcinolone acetonide ointment USP, 0.5 per cent of Perrigo New York, Inc. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 25, 2016 Category: Pharmaceuticals Source Type: news

Teligent, Inc. Receives Two FDA Approvals For Topical Prescription Portfolio
Represent the Fifth and Sixth FDA Approvals of the Year, Launches Planned for This Quarter BUENA, N.J., July 8, 2016 -- (Healthcare Sales & Marketing Network) -- Teligent, Inc. (TLGT), a New Jersey-based specialty generic pharmaceutical company, announ... Biopharmaceuticals, Generics, FDATeligent, Triamcinolone Acetonide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 8, 2016 Category: Pharmaceuticals Source Type: news

Glenmark gets USFDA final nod for anti-fungal ointment
Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for nystatin and triamcinolone acetonide ointment. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 24, 2016 Category: Pharmaceuticals Source Type: news

Clearside Biomedical floats $50m IPO
Clearside Biomedical raised $50 million with its initial public offering, floating 7.2 million shares at $7 apiece. That’s below the range Clearside earlier set for the IPO, when it planned to put up 4.0 million shares at a range of $14 to $16, for a midpoint value of $60 million. Alpharetta, Ga.-based Clearside is developing a drug-device combination to treat macular edema using CLS-TA triamcinolone acetonide and its SCS microinjector. The device is designed to inject the compound in the suprachoroidal space, the 30-µm  gap between the choroid and the sclera. A Phas...
Source: Mass Device - June 2, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Funding Roundup Initial Public Offering (IPO) Optical/Ophthalmic Clearside Biomedical Source Type: news

Trianex (Triamcinolone Acetonide Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 21, 2016 Category: Drugs & Pharmacology Source Type: news

Anika Therapeutics wins CE Mark for Cingal knee treatment
Anika Therapeutics said today it won CE Mark approval in the European Union for its Cingal drug-combo designed to treat osteoarthritis-related knee pain. Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the Bedford, Mass.-based company said. “The European approval of Cingal marks an important milestone for Anika as it advances our global expansion strategy, provides a platform for us to demonstrate our commercialization capabilities, and most importantly, reinforces the product’s tr...
Source: Mass Device - March 28, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Orthopedics Regulatory/Clearance Anika Therapeutics Inc. Source Type: news

Advantages Claimed for Dropless Cataract SurgeryAdvantages Claimed for Dropless Cataract Surgery
Use of a combined triamcinolone/moxifloxacin compound improves therapeutic compliance, enhances prophylaxis against infection, and costs less than conventional eyedrops. Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 21, 2015 Category: Consumer Health News Tags: Ophthalmology Article Source Type: news

Anika assigned to FDA’s drug eval arm for Cingal approval
Anika Therapeutics today said the FDA’s Office of Combination Products assigned the company’s Cingal drug-combo to its Center for Drug Evaluation and Research arm to pursue premarket regulatory approval. Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the company said. “While we strongly disagree with the FDA’s decision, as our position of Cingal’s device-lead classification is supported by both regulations and scientific data, we intend to proceed expeditiously to mov...
Source: Mass Device - December 9, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Pre-Market Approval (PMA) Food & Drug Administration (FDA) Regulatory/Compliance Anika Therapeutics Inc. Source Type: news

Clearside Biomedical raises $14.4m, enrolls 1st patient in Phase III trial
Clearside Biomedical raised $14.4 million in a new round of equity financing, and said yesterday it enrolled the 1st patient in the Phase 3 Peachtree clinical trial of its CLS-TA for treating patients with macular edema associated with non-infectious uveitis. Clearside is developing CLS-TA triamcinolone acetonide to be delivered using its proprietary SCS microinjector for patients with macular adema. The device is designed to inject the compound in the suprachoroidal space, a gap no wider than 30 µm between the choroid and the sclera that extends from the anterior portion of the eye to the posterior near th...
Source: Mass Device - December 8, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Optical/Ophthalmic Drug-Device Combinations Business/Financial News Clearside Biomedical Source Type: news

Clearside closes patient enrolment in Phase II Dogwood trial of CLS-TA to treat macular edema
US clinical-stage biopharmaceutical firm Clearside Biomedical has completed patient enrolment in its Phase II clinical trial (Dogwood) of CLS-TA, its proprietary form of triamcinolone acetonide, to treat macular edema associated with non-infectious u… (Source: Drug Development Technology)
Source: Drug Development Technology - October 12, 2015 Category: Pharmaceuticals Source Type: news

Intraocular Pressure Elevations Common After Intravitreal Triamcinolone InjectionsIntraocular Pressure Elevations Common After Intravitreal Triamcinolone Injections
Intraocular pressure elevations are common after intravitreal injections of triamcinolone acetonide for macular edema resulting from retinal vein occlusion, according to data from the SCORE study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 26, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Clearside starts Phase II trial of CLS-TA to treat macular edema associated with RVO
US-based biopharmaceutical firm Clearside Biomedical has started patient enrolment in a Phase II trial of its proprietary formulation of triamcinolone acetonide, CLS-TA, to treat macular edema associated with retinal vein occlusion (RVO). (Source: Drug Development Technology)
Source: Drug Development Technology - March 3, 2015 Category: Pharmaceuticals Source Type: news

Is A Specific Corticosteroid Better for Treatment of Asthma Than Another?
Discussion Asthma is a chronic obstructive lung disease that affects many children and adults. There is a wide range of symptoms that people experience from occurring relatively rarely (ie intermittent asthma) to patients having daily symptoms of such intensity that they are life-threatening (ie chronic severe asthma). The goals of asthma management include patient education and medication management so patients have no or minimal symptoms, prevent exacerbations, have no activity restrictions, have normal pulmonary function tests, have no or minimal medication side effects and meet patient and family expectations. Well con...
Source: PediatricEducation.org - January 5, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Flexion Therapeutics starts Phase IIb trial of pain drug to treat osteoarthritis
US-based Flexion Therapeutics has dosed its first patient in a confirmatory Phase IIb clinical trial of its new, non-opioid, sustained-release, intra-articular (IA) formulation of triamcinolone acetonide (TCA) 'FX006' as a treatment for relieving pai… (Source: Drug Development Technology)
Source: Drug Development Technology - April 30, 2014 Category: Pharmaceuticals Source Type: news

Nasacort Allergy Spray Going OTC
(MedPage Today) -- The allergy nasal spray triamcinolone acetonide (Nasacort AQ) has been cleared for over-the-counter sale, drugmaker Sanofi announced. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - October 12, 2013 Category: Allergy & Immunology Source Type: news

FDA Panel Favors Nasacort OTC Switch
(MedPage Today) -- SILVER SPRING, Md. -- An FDA advisory committee voted Wednesday to make allergy nasal spray triamcinolone acetonide (Nasacort AQ) available without a prescription -- but some expressed concern about its use in children. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - August 2, 2013 Category: Allergy & Immunology Source Type: news